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Abstract
Introduction—A variation in bone response to fluoride (F−) exposure has been attributed to genetic
factors. Increasing fluoride doses (0ppm, 25ppm, 50ppm, 100ppm) for three inbred mouse strains
with different susceptibilities to developing dental enamel fluorosis (A/J, a “susceptible” strain;
SWR/J, an “intermediate” strain; 129P3/J, a “resistant” strain) had different effects on their cortical
and trabecular bone mechanical properties. In this paper, the structural and material properties of the
bone were evaluated to explain the previously observed changes in mechanical properties.
Materials and Methods—This study assessed the effect of increasing fluoride doses on the bone
formation, microarchitecture, mineralization and microhardness of the A/J, SWR/J and 129P3/J
mouse strains. Bone microarchitecture was quantified with microcomputed tomography and strut
analysis. Bone formation was evaluated by static histomorphometry. Bone mineralization was
quantified with backscattered electron (BSE) imaging and powder x-ray diffraction. Microhardness
measurements were taken from the vertebral bodies (cortical and trabecular bone) and the cortex of
the distal femur.
Results—Fluoride treatment had no significant effect on bone microarchitecture for any of the
strains. All three strains demonstrated a significant increase in osteoid formation at the largest fluoride
dose. Vertebral body trabecular bone BSE imaging revealed significantly decreased mineralization
heterogeneity in the SWR/J strain at 50ppm and 100ppm F−. The trabecular and cortical bone
mineralization profiles showed a non-significant shift towards higher mineralization with increasing
F− dose in the three strains. Powder x-ray diffraction showed significantly smaller crystals for the
129P3/J strain, and increased crystal width with increasing F− dose for all strains. There was no effect
of F− on trabecular and cortical bone microhardness.
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Conclusion—Fluoride treatment had no significant effect on bone microarchitecture in these three
strains. The increased osteoid formation and decreased mineralization heterogeneity support the
theory that F− delays mineralization of new bone. The increasing crystal width with increasing F−
dose confirms earlier results and correlates with most of the decreased mechanical properties. An
increase in bone F− may affect the mineral-organic interfacial bonding and/or bone matrix proteins,
interfering with bone crystal growth inhibition on the crystallite faces as well as bonding between
the mineral and organic interface. The smaller bone crystallites of the 129P3/J (resistant) strain may
indicate a stronger organic/inorganic interface, reducing crystallite growth rate and increasing
interfacial mechanical strength.
Keywords
fluoride; bone quality; genetic susceptibility / resistance; hydroxyapatite crystals; mineralorganic
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INTRODUCTION
Fluoride (F−) is a trace element that is incorporated into bone mineral during bone formation
[1]. Fluoride substitutes for the hydroxyl group in hydroxyapatite, forming fluorapatite. The
action of fluoride on bone has been extensively studied and this ion has been shown to have
an effect on bone mineral, bone cells and bone architecture [1]. The dose-dependent effects on
mechanical properties are well-known, but the underlying mechanisms are still not fully
understood. Furthermore, dose level alone is not the only factor affecting bone quality; the role
of genetic factors has been emphasized in some epidemiological and clinical studies. Previous
studies provide evidence of human non-responder populations to F− [2] while some populations
seem to be very sensitive to F− at a wide range of doses [3,4,5,6,7]. Three inbred strains of
mice (A/J, SWR/J, 129P3/J) that displayed variations in the onset and severity of dental/enamel
fluorosis with equivalent F− exposure [8], were shown to have different reductions in bone
mechanical properties with equivalent F− concentrations in their mineralized tissues [9]. The
bone mechanical properties were reduced in the “susceptible strain” (A/J), moderately altered
in the “intermediate strain” (SWR/J) and unaffected in the “resistant strain” (129P3/J),
suggesting a genetic contribution to the variation in bone response to F− content.
The purpose of this study was to assess the effects of increasing F− doses on bone properties
at the microscopic level (architecture, geometry, histology) and on bone mineralization,
crystallite size and microhardness for the A/J, SWR/J and 129P3/J mouse strains in order to
determine a possible mechanism for the previously reported differences in bone mechanical
properties caused by F− exposure.
MATERIALS AND METHODS
Animal husbandry
Mice—The bones used in this study were obtained from mice used for a previous study [9].
These were weanling (3-week-old) male mice from A/J, SWR/J, and 129P3/J inbred strains
obtained from The Jackson Laboratory (Bar Harbor, ME). These three strains were selected
because of differences in susceptibility to develop dental fluorosis (A/J is a “susceptible” strain,
SWR/J is an “intermediate” strain and 129P3/J is a “resistant” strain) [8] as well as a varied
response of bone mechanical properties to fluoride exposure [9]. This study was approved by
the Indiana University School of Dentistry IACUC and all mice were housed within the Indiana
University School of Dentistry Bioresearch Facility, an AAALAC-accredited unit. Mice were
contained in boxed caging and allowed food and water ad libitum. They were fed a laboratory
rodent diet (#5001, PMI® Nutrition International, Richmond, IN) that contained, by dry
weight, 0.95% calcium, 0.67% phosphorus, 4.5IU/g vitamin D3, and 18ppm fluoride.
Mousny et al. Page 2













Fluoride Treatment—The deionized water was tested from multiple sites within the IUSD
Bioresearch Facility and showed [F] ion = 0.02 + 0.01 ppm. NaF was used to raise the [F] ion
to 25ppm, 50ppm and 100ppm. Four levels of fluoride (0, 25, 50 and 100ppm F−) were thus
delivered in the drinking water as NaF from 3 weeks of age, for a period of 42 days. Deionized
and fluoridated water was periodically analyzed by ion specific electrode (ISE) for fluoride
concentration. Each batch of prepared 25ppm, 50ppm, and 100ppm water for the study was
used only if the fluoride was within 4% of the target concentration. Each treatment group
consisted of 6 mice, except for the A/J (25ppm), A/J (50ppm) and 129P3/J (100ppm) groups
which consisted of 7 mice. At the end of the F− treatment, the mice were humanely euthanized.
Selected bones were harvested for analysis.
Design of experiment
Preparation of Bones—The lumbar vertebral bodies (VB) and femora (F) were dissected
and kept moist with saline solution during preparation. They were stored at −20°C.
Strut analysis—Distal thoracic vertebral bodies were used for strut analysis. Each vertebra
was cleaned and trimmed to leave only the vertebral body. They were fixed in 10% neutral
buffered formalin for one week. Samples were then dehydrated in ascending concentrations of
acetone and subsequently infiltrated in ascending ratios of unpolymerized Spurr resin and
acetone. The bones were finally embedded in blocks of Spurr resin that was polymerized in a
60°C oven for 48 hours. Several 5-micron thick coronal sections were then cut from each
sample, using an automatic Reichert-Jung 2500 rotary microtome (Leica Microsystems).
Sections were placed on gelatinized slides and incubated in a 60°C oven for 48 hours, then
stained with Von Kossa and imaged using light microscopy. Trabecular bone area was analyzed
using the Quantimet 570 (Leica) image processing and analysis system. The connectivity was
evaluated by skeletonizing the image of trabecular bone, representing the trabeculae as struts.
Nodes represented points at which three or more struts were connected. The number of nodes
(NN;mm−2) was determined as a measure of connectivity, and the number of free ends
(NFE;mm−2) was determined as a measure of disconnectivity [10].
Microcomputed tomography of thoracic vertebral bodies—Thoracic vertebral
bodies were scanned using microcomputed tomography (µCT) to evaluate the trabecular bone
architecture (Figure 1). These vertebrae were embedded in microtubes using epoxy resin to
eliminate movement during the scan. µCT was performed using a desktop µCT with a 6.5 µm
voxel size (GE Medical Systems eXplore Locus SP Specimen Scanner, London, Ontario,
Canada). Scans were reconstructed and calibrated using a hydroxyapatite standard. Final
images and 3D volumes were analyzed using MicroView CT visualization software (GE
Medical Systems, London, Ontario, Canada). Each vertebral body was cropped out of the
reconstructed volume and rotated so that the mediolateral axis coincided with the x-axis. The
region of interest (trabecular bone) was then defined in each vertebral body 3D image and
analyzed to determine the following trabecular bone parameters: bone volume fraction
(BVF=Bone Volume/Total Volume; %), bone surface area (SA; mm2), mean trabecular
thickness (TbTh; µm), trabecular number (TbN; mm−1), and mean trabecular separation (TbSp;
µm). The structure model index (SMI) was also determined. SMI gives information about the
curvature of the surface and estimates how “plate-like” or “rod-like” a trabecular structure is.
A SMI value of zero indicates bone architecture with “plates” while a SMI value of 3 is an
indicator of “rods”. Anisotropy was analyzed by determining the ratio between the length of
one axis versus another (a1/a3, a1/a2, a2/a3). This allowed us to determine the degree of
symmetry and orientation of the trabecular structure: the closer the ratio is to 1, the less
anisotropic the sample.
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Static histomorphometry—Coronal sections at midpoint of the embedded vertebral bodies
used for strut analysis were stained with Goldner’s trichrome, resulting in blue/green staining
of mineralized bone and red/orange staining of osteoid [11]. Trabecular bone was analyzed
using a 25x objective lens (Zeiss) connected to a video camera (Retiga 1300). The total
trabecular area was analyzed as serial fields using the Leitz Bioquant morphometry system
(Bioquant Nova Prime, Version 6.50.10). We determined the following static
histomorphometric parameters: trabecular bone volume (BV/TV; %; ratio between trabecular
bone volume and tissue volume), mineralized trabecular bone volume (MdV/TV; %; ratio
between mineralized trabecular bone volume and tissue volume), osteoid volume (OV/BV; %;
ratio between osteoid volume and bone volume), osteoid surface (OS/BS; %; ratio between
total osteoid surface and bone surface) and osteoid thickness (OTh; µm).
Backscattered electron imaging—Following three-point bending of right femora, as
reported in a previous study [9], the distal end of the broken femur was embedded in Spurr
blocks, using the same procedure as described for the vertebral bodies. The embedded femora
as well as the Spurr-embedded blocks of thoracic vertebral bodies were used for evaluation of
mineralization distribution using backscattered electron (BSE) imaging. Blocks were cut,
polished, carbon-coated and imaged using backscattered electron (BSE) imaging (solid state
BSE detector, FEI Company, Hillsboro, OR, USA) on a Philips XL30 ESEM (FEI). The
relative backscattering of the mineralized tissues was determined by comparison with a silicon
dioxide standard, which was measured between every specimen. Histograms of the grey level
distribution were created for the trabecular bone of the vertebral bodies and for the distal femur
cortex. Increasing brightness corresponds with increasing mineralization [12]. From the
histogram, the grey level of the histogram peak was determined and used to represent the overall
degree of mineralization. The full width at half the maximum height (FWHM) of the histogram
represents the heterogeneity of the mineralization distribution, and gives an approximation of
the distribution of less-mineralized (younger) and more mineralized (older) bone.
Powder x-ray diffraction/apatite crystallite size—Powder x-ray diffraction was
performed on bone powder, produced from left femora that were previously used to determine
femur fluoride concentration [9]. The powder was prepared as follows: Bones were manually
crushed, tri-washed and lyophilized for 48 hours. A 2:1 chloroform:methanol solution was
used to defat the specimens overnight [13]. The solution was decanted and replaced with
methanol. After one hour, the methanol was decanted and the specimens dried at ambient
temperature. Dry specimens were ground to a powder (< 45 µm particle size) using a cryogenic
freezer mill (SPEX Certiprep 6750 Freezer Mill).
The bone powder specimens and a NIST standard reference material (2910, Calcium
Hydroxyapatite) were scanned from 24.5 to 27.0 °2θ at a scan speed of 0.1 °2θ/min and 37.0
to 42.0 °2θ at a scan speed of 0.05 °2θ/min (step size 0.004 °2θ, 40 kV, 30 mA, Cu Kα radiation,
Rigaku MultiFlex, Rigaku/MSC, The Woodlands, TX, USA). All specimens were remounted
and re-scanned for a total of 3 scans/specimen. Crystallite size was calculated from the peak
broadening of the powder x-ray diffraction peaks [14].
Peak broadening is quantified with the “full width at half the maximum height” (FWHM) of
the peak (β1/2), which is composed of broadening caused by both the specimen and the
instrument. The FWHM of the 26 °2θ peak ((002) plane-hydroxyapatite crystal length) and 40
°2θ peak ((310) plane-hydroxyapatite crystal cross-section or width) were quantified with the
profile fitting function of Jade (XRD pattern processing software, v. 6.5, Materials Data Inc.).
The FWHM due to the instrument (instrument broadening (βi)), was measured by scanning
reference silicon at 26 and 55 °2θ. The broadening due to the specimen only (corrected β1/2)
was calculated from the square root of the instrument broadening squared subtracted from the
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measured specimen peak broadening squared. This corrected β1/2 was used to calculate the
crystalline size between the (002) and the (310) planes using the Scherrer equation,
where 57.3 is a conversion factor from degrees to radians, K is a correction factor (0.9) used
to reflect the elongated apatite crystals of bone, λ is the K-emission wavelength of copper, θ
is the diffraction angle, and D is the size of the crystallite in angstroms along the specific axis.
The means of three independent FWHM values for each 26 and 40 °2θ peak were calculated
for each specimen.
Cortical and trabecular microhardness—After the BSE study was complete,
microhardness measurements of the Spurr-embedded thoracic vertebral bodies and distal
femora were performed. The microhardness of trabecular bone (coronal surface of vertebral
bodies) and cortical bone (coronal plane of vertebral body cortical shell and axial surface of
distal femora) was determined by using a microhardness testing machine (Mitutoyo HM-122,
S/N 260113). Microhardness testing consists of measuring the resistance of bone to indentation.
During the test, a pyramidal diamond indenter of known geometry was lowered onto the sample
under a known load for 10 seconds, leaving an indentation on its surface. The depth of the
indentation is related to the hardness of the bone. Given that the diamond is pyramidal, there
is a linear relationship between the length of the indentation and the depth. Length can therefore
be used as a proxy measure for depth. The indentation length and the load are used to calculate
the hardness of the bone, using this equation:
Where HV is the Vickers Hardness, k is a constant ( , where g is the standard
acceleration due to gravity), F is the test force (0.025kg), S is the surface area of indentation
(mm2), d is the average length of two diagonals (mm), and θ is the face-to-face apex angle of
diamond indenter (136°). Ten measures were performed for each type of bone (trabecular/
cortical) for each sample and the average of these ten measures was calculated.
Statistical analysis
Statistical analysis was performed using SPSS (version 12.0) (SPSS Inc., Chicago IL) software.
Two-way Analysis of Variance (ANOVA, general linear model) was used to compare the
effects of F− treatment and genetic strain on the bone properties. Post hoc multiple comparisons
between the three strains and four fluoride treatments were performed using the Bonferroni
test. The correlation between the crystallite width and mechanical properties for each strain
was made with the bivariate correlation function (SPSS) with a two-tailed Pearson coefficient.
A p value of ≤ 0.05 was required to consider a difference significant. A confidence level of
90% (p < 0.1) indicated a statistical trend. Data are presented as mean ± SD.
RESULTS
Strut analysis
There were no significant changes in the thoracic VB trabecular bone connectivity with fluoride
treatment in the three strains (Table 1).
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Microcomputed tomography of thoracic vertebral bodies
Analysis of the trabecular bone parameters (BVF, SA, TbTh, TbN and TbSp) did not show
any significant differences between the groups (Table 1). No statistical differences were
observed between SMI values (Table 1). Anisotropy analysis (a1/a3, a1/a2, a2/a3) did not show
any significant change with fluoride treatment within the three strains (Table 1).
Static histomorphometry
The only significant histomorphometric differences observed were in osteoid formation (Table
2). There was an increase in osteoid volume and osteoid surface between the control and the
100ppm groups for all three strains. The increase observed in osteoid thickness was statistically
significant for the 129P3/J strain. The percent increase in osteoid volume for the three strains
correlated with their susceptibility to dental fluorosis, with a 26-fold increase for the A/J strain,
a 7-fold increase for the SWR/J and a 6-fold increase for the 129P3/J strain. The osteoid surface
followed a similar trend, with a 46-fold increase for the A/J, a 5-fold for the SWR/J and a 4-
fold increase for the 129P3/J strain. This trend also applied to osteoid thickness, with a 4-fold
increase for the A/J, a 2-fold increase for the SWR/J and a 1.3-fold increase for the 129 P3/J
strain. The comparison of the three strains for each fluoride dose treatment showed that the
osteoid volume and surface were significantly larger in the 129P3/J strain (p ≤0.05).
Backscattered electron imaging
The average peak grey level of femur cortical bone increased with fluoride treatment, but the
observed differences were not statistically significant (Table 3). Grey levels increased by 2%
in the A/J strain, by 8% in the SWR/J strain and by 12% in the 129P3/J strain at 100ppm F−.
The FWHM did not demonstrate any significant changes in the three strains (Table 3).
While the average peak grey level of vertebral body trabecular bone increased with fluoride
treatment, the observed differences were not statistically significant (Table 3). Grey level
increased by 7% in A/J, by 20% in SWR/J and by 12% in 129P3/J (Table 3). While the FWHM
decreased in the three strains with F− treatment, these changes were only significant in the
SWR/J (Table 3). The FWHM decreased by 4% in A/J, by 22% in SWR/J and by 21% in
129P3/J.
X-ray diffraction study
A 2-way ANOVA analysis of the effect of genotype and fluoride dose on the crystal length
(002) showed an effect of genotype on crystallite length, independent of fluoride dose. The
crystallite length of the resistant (129P3/J) strain was significantly smaller than the same
dimension for the other strains (p < 0.05) (Table 4). The F− treatment did not significantly
affect the crystal length in any of the three strains.
A similar analysis for the crystallite width (310) showed an effect of both genotype and fluoride
concentration, with no evidence of interaction between the two factors. The crystallite width
of the 129P3/J strain was significantly smaller than for the A/J and SWR/J strains (p < 0.05)
(Table 4). All strains showed a significant increase in crystallite width between 0 and 100ppm
F− (Table 4). The susceptible strain A/J showed a 5.7% increase in crystallite width, the
intermediate strain SWR/J showed a 10.6% increase and the resistant strain 129P3/J showed
a 8% increase. At 100ppm F− dose treatment, the crystallite width of the resistant strain 129P3/
J was still significantly smaller than for the two otherstrains (p < 0.05).
The correlation analysis between the crystallite width and mechanical properties (from a
previous study [9]) for each strain at all F− dose treatments showed that the crystallite width
increase correlated with most of the decreased mechanical properties described in the
susceptible (A/J) and intermediate (SWR/J) strains (Table 5, Figure 2).
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Cortical and trabecular bone microhardness
No statistically significant differences were observed between the microhardness values of the
cortical or the trabecular bone between the three strains at any F− concentration (Table 6).
DISCUSSION
In our previous study [9], we showed that increasing doses of fluoride (0ppm, 25ppm, 50ppm,
100ppm) had different effects on the bone properties of three inbred mouse strains which
demonstrated different susceptibilities to developing enamel fluorosis (A/J, a “susceptible”
strain; SWR/J, an “intermediate” strain; 129P3/J, a “resistant” strain). Although significant
increases of fluoride concentration in femora and vertebral bodies could be demonstrated, and
no significant effects on bone macroarchitecture and bone mineral densities (BMD) were found
in the three strains, mechanical testing showed significant degradation of bone mechanical
properties in the A/J strain, whereas moderate degradation in the SWR/J strain and no effect
in the 129P3/J strain were observed. We concluded that genetic factors may contribute to the
variation in bone response to fluoride exposure and that the differences observed between the
three strains could not be explained by an alteration of the bone macroarchitecture or by a
different influence of fluoride on BMD. The purpose of this study was to determine if
microarchitecture, histomorphometry, mineralization or microhardness were influenced by
fluoride treatments and could be correlated with the previously observed reduction in bone
mechanical properties.
Regarding bone microarchitecture, neither microcomputed tomography of thoracic vertebral
body nor strut analysis showed any significant changes with fluoride treatment in the three
strains. Fluoride therapy has been showed to increase trabecular thickness but to leave
connectivity unaltered [15]. In our study, we did not find any change in vertebral body
connectivity or in trabecular thickness. The absence of significant changes may be explained
by the fact that fluoride was administered for only 42 days, which may be too short a period
of time to have any significant effect on trabecular thickness. Therefore the differences in bone
mechanical properties observed for the A/J and SWR/J strains with fluoride treatment [9]
cannot be explained by altered bone microarchitecture.
It is recognized that fluoride is usually not incorporated into fully-mineralized, mature bone
and accumulates only in bone formed during the period of fluoride exposure [16]. This explains
why fluoride concentration is generally higher in sites with a high turnover rate, such as
cancellous rather than cortical bone. In our study, fluoride was given to young (that is, rapidly
growing) mice and this explains the significant increases (concordant with increasing fluoride
dose) of fluoride concentration observed in femora and vertebral bodies in all three strains
[9]. As noted in our previous paper, we selected fluoride concentration in the water that would
yield serum concentrations of ~8 µmol/L at 50ppm and ~12 µmol/L at 100ppm, which are
greater than the plasma fluoride concentrations measured in humans when drinking water is
optimally fluoridated (0.5–1.5 µmol/L) [17], but which do correspond to the therapeutic range
of fluoride for osteoporosis treatment (5–10 µmol/L). High doses of fluoride were shown to
affect bone cells and therefore remodeling processes. Fluoride has been shown to have a
mitogenic effect on osteoblasts [18,19,20]. Effects of fluoride on steoclasts have also been
described [21], and fluoride effects on osteoclastogenesis have been demonstrated to be
influenced by genetic background [22]. The cumulative result of these effects is a net increase
in bone formation. This is consistent with our observations of osteoid formation in all three
mouse strains; the osteoid formation was the only parameter that showed significant changes.
In all three strains, we noted a significant increase in osteoid formation at the largest fluoride
dose. The percent increase in osteoid volume, surface and thickness for the three strains
correlated with their susceptibility to dental fluorosis, but the overall osteoid formation was
significantly larger in the 129P3/J strain
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Fluoride has also been shown to have an effect on mineralization. It retards mineralization and
the mineral produced is less susceptible to dissolution [23,24,25]. Alterations in bone crystal
structure have also been described [24]. In our study, the BSE mineralization profile of cortical
and trabecular bone showed a non-significant increase towards higher mineralization with
increasing F− dose in the three strains. This is consistent with the increased resistance to
dissolution of bone mineral with an increased fluoride content. Fluoride treatment had different
effects on mineralization heterogeneity of the trabecular and cortical bone. We observed a
decrease in mineralization heterogeneity in the trabecular bone, which was consistent with
observations that fluoride delays mineralization of new bone. The absence of an effect on
cortical bone mineralization heterogeneity may be explained by site-specific differences in
bone turnover, as there is a higher turnover in trabecular bone.
It remains unclear if the substitution of fluoride ions for hydroxyl ions affects the size of the
crystallites. Most authors accept that the crystal length is unchanged in F− treatment [26,27];
however there remains debate about changes in crystal width. Some authors described an
increase in crystal width [26,28,29], while others found no significant changes [27]. In this
study, we observed a significant increase in crystal width at the largest F− dose for all three
strains. This relative increase in crystal width was similar in the three strains. However the
absolute crystal size (length and width) was also inherently different between the strains. The
129P3/J (“resistant”) strain had smaller crystals in both measured dimensions than the other
strains for all fluoride doses. The overall smaller crystal size suggests that the crystal growth
rate of the resistant strain is slower than that of the other strains. This reduced crystal growth
rate may be due to different mineral-collagen interface conditions that reduce the flux of
calcium and phosphate ions to the apatite crystal surface.
We found a correlation between the crystallite width increase and most of the observed
decreased mechanical properties in the A/J and SWR/J strains (Table 5, Figure 2). These
observations suggest that bone crystal size may play an important role in determining bone
quality. The fact that the 129P3/J resistant strain has the strongest bone and the smallest bone
crystal may suggest that these mice have a stronger mineral-organic interfacial bonding, which
has previously been shown to play an important role in bone quality [30]. The quality of the
mineral-organic interfacial bonding and/or bone matrix proteins could therefore be influenced
by genetics, and the observed differences between the three strains may be explained by
different genetic factors whose specific action is still not known.
To test bone mechanical properties at the microscopic level, we performed a microhardness
study of trabecular bone (thoracic vertebral body) and cortical bone (thoracic vertebral body
and distal femur). This test has the theoretical advantage of eliminating architectural
considerations, instead focusing on the tissue-level mechanical properties of the bone. In our
study, we did not find statistically significant F− induced changes in trabecular and cortical
bone microhardness for any of the three strains. These results may be influenced by the lack
of precision of this test. Variations in trabecular shape, orientation and number, as well as
variations in mineral distribution and properties throughout individual trabeculae, are known
to influence the results of this test [31]. This lack of precision is also present in cortical bone
microhardness study, as we tested femur and VB cortical bone microhardness at one cross-
section only. The absence of any change in microhardness may also be explained by the short
period of fluoride treatment and by the fact that F− was given to rapidly growing mice.
Therefore we cannot draw any certain conclusions from the absence of significant differences
in the results.
In conclusion, fluoride is known to have biological effects on bone cells, as well as chemical
and physical effects on bone crystals. In the present study, fluoride treatment had no effect on
bone microarchitecture in the three strains. The increased osteoid formation and decreased
Mousny et al. Page 8













mineralization heterogeneity support the theories that F− stimulates osteoblastic activity and
delays mineralization of new bone. The 129P3/J resistant strain was shown to have smaller
bone crystals and a correlation was found between the F− induced increase in crystal width and
most of the decreased mechanical properties. Interfacial bonding interactions between the
mineral and organic phases of bone have been shown to play an important role in bone
mechanical properties [32], and different types of interaction have been described [33,34,35,
36,37]. In Figure 3, we propose a model that could explain the effect of mineral-collagen
interface quality and fluoride concentration on crystal growth and composite material strength.
At low fluoride dose (Figure 3, a and b), the 129P3/J resistant strain has a stronger organic-
inorganic interface than the strains A/J and SWR/J. This strong interfacial bonding may reduce
crystallite growth rate, explaining the smaller bone crystals discovered in the 129P3/J strain,
and may increase the composite material strength. In vitro studies have demonstrated that
fluoride ions could alter bone mechanical properties by altering mineral-organic interfacial
bonding [32,38,39]. At high fluoride dose (Figure 3, c and d), such interfacial bonding alteration
could weaken the mineral-organic bond and reduce interfacial mechanical strength. The weaker
mineral-organic interface allows an increased flux of calcium and phosphate ions to the apatite
crystal surface, which explains the increased crystal width observed in the three strains. This
increase in crystal width was similar in the three strains and the resistant 129P3/J strain had
still the smallest bone crystals at high fluoride dose, which may explain the absence of bone
mechanical properties alteration in this strain.
Another possible mechanism of fluoride action would be an alteration of bone matrix proteins,
i.e. collagen and noncollagenous proteins. Collagen and noncollagenous proteins are of
significant importance for the biomechanical integrity of the bone [31,40,41,42,43] and many
bone matrix proteins play important roles in mineralization [44]. Miao et al. [45] have
investigated the effects of fluoride treatment (221 mg/L NaF in drinking water for two months)
on rat calvarial osteoblasts. They showed that excessive fluoride intake could inhibit the
synthesis of type I collagen and decrease the degree of collagen cross-linking. An influence of
fluoride on proteoglycan structure synthesized by mineralizing bone cells [46] and on
expression of matrix metalloproteinases [47] has also been proposed. Kindt et al. (39) showed
that enhanced formation of superficial fluoroapatite weakened the protein-hydroxyapatite
interfaces but NaF was also found to be a potent agent for extracting noncollagenous proteins
from bone powder. It must be pointed out that these effects were demonstrated in in vitro studies
and that they may be different in vivo.
Bone quality is thus a complex property that we do not fully understand, and the way the
fluoride alters bone quality is still unclear. Possible mechanisms would be an alteration of
mineral-organic interfacial bonding and/or an effect on bone matrix proteins. The present study
also emphasizes the importance of considering bone mineral crystal size, mineral-organic
interfacial bonding and bone matrix proteins in understanding bone quality. This has an
important clinical impact, as alterations in bone collagen quality has been observed with aging
[48].
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Coronal section of a thoracic vertebral body, obtained with microcomputed tomography.
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Correlation analysis between the crystallite width and femur ultimate stress for each strain at
all F− dose treatments. Crystallite width increase correlates with the decreased femur ultimate
stress observed in the susceptible (A/J) and intermediate (SWR/J) strains.
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Schematic of the effect of mineral-collagen interface quality and fluoride concentration on
crystal growth and composite material strength.
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TABLE 1
Evaluation of thoracic vertebral body trabecular bone connectivity by strut analysis. Analysis of the number of free
ends (NFE, disconnectivity) and of the number of nodes (NN, connectivity). Trabecular bone parameters (BVF, SA,
TbTh, TbN and TbSp), SMI and anisotropy analysis of the thoracic vertebral body in the three strains.
Fluoride Treatment (ppm) Strain A/J Strain SWR/J Strain 129P3/J
NFE
0 39.67 ± 7.24 42.51 ± 12.83 38.05 ± 8.41
100 39.25 ± 8.55 50.88 ± 7.09 47.08 ± 7.39
NN
0 10.24 ± 3.26 20.76 ± 3.80 25.36 ± 9.24
100 7.25 ± 2.26 14.87 ± 5.71 24.36 ± 4.29
BVF (%)
0 0.22 ± 0.03 0.27 ± 0.03 0.30 ± 0.03
100 0.20 ± 0.02 0.26 ± 0.02 0.27 ± 0.02
SA (mm2)
0 23.58 ± 2.94 27.68 ± 4.42 41.08 ± 4.18
100 23.64 ± 6.45 28.63 ± 3.88 35.25 ± 7.22
Tb.Th. (µm)
0 0.026 ± 0.002 0.026 ± 0.004 0.028 ± 0.003
100 0.024 ± 0.003 0.025 ± 0.002 0.027 ± 0.002
Tb.N. (mm−1)
0 8.66 ± 1.19 10.03 ± 0.98 10.66 ± 0.43
100 8.55 ± 1.55 10.22 ± 0.83 9.92 ± 1.20
Tb.Sp. (µm)
0 0.091 ± 0.014 0.074 ± 0.008 0.066 ± 0.003
100 0.097 ± 0.021 0.073 ± 0.007 0.075 ± 0.012
SMI
0 1.06 ± 0.40 0.47 ± 0.57 0.37 ± 0.35
100 1.06 ± 0.38 0.69 ± 0.22 0.48 ± 0.28
a1/a3
0 1.73 ± 0.08 1.46 ± 0.07 1.52 ± 0.04
100 1.51 ± 0.20 1.45 ± 0.09 1.55 ± 0.13
a1/a2
0 1.53 ± 0.07 1.37 ± 0.05 1.41 ± 0.06
100 1.32 ± 0.17 1.35 ± 0.03 1.38 ± 0.13
a2/a3
0 1.13 ± 0.07 1.07 ± 0.04 1.08 ± 0.04
100 1.14 ± 0.05 1.07 ± 0.05 1.12 ± 0.06
Data are presented as means ± SD. No significant statistical differences were noted.
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TABLE 2
Histomorphometric analysis of the thoracic vertebral body in the three strains.
Fluoride Treatment (ppm) Strain A/J Strain SWR/J Strain 129P3/J
% Bone Volume of Tissue
Volume BV/TV
0 11.48 ± 2.86 19.83 ± 3.15 24.65 ± 8.66
25 12.55 ± 3.11 18.36 ± 3.54 24.50 ± 4.50
50 13.58 ± 2.64 20.46 ± 4.72 23.69 ± 6.93
100 12.85 ± 1.62 15.44 ± 2.89 24.43 ± 2.97
% Mineralized Bone of Tissue
Volume MdV/TV
0 11.47 ± 2.84 19.83 ± 3.15 24.62 ± 8.64
25 12.54 ± 3.11 18.35 ± 3.53 24.49 ± 4.50
50 13.58 ± 2.64 20.45 ± 4.72 23.64 ± 6.93
100 12.81 ± 1.62 15.43 ± 2.89 24.27 ± 2.94
% Osteoid Volume of Bone
Volume OV/BV
0 0.01 ± 0.01 0.01 ± 0.02 0.11 ± 0.07
25 0.02 ± 0.03 0.05 ± 0.05 0.05 ± 0.03
50 0.04 ± 0.04 0.03 ± 0.03 0.20 ± 0.07
100 0.26 ± 0.05** 0.07 ± 0.03 0.64 ± 0.32 ***
% Osteoid Surface(OS/BS)
0 0.09 ± 0.19 0.22 ± 0.39 2.51 ± 1.65
25 0.32 ± 0.45 0.54 ± 0.69 1.04 ± 0.83
50 0.67 ± 0.59 0.40 ± 0.25 4.05 ± 1.18
100 4.10 ± 0.91*** 1.20 ± 0.54 * 9.40 ± 3.48 ***
Osteoid Thickness (mcm) OTh
0 0.38 ± 0.52 0.68 ± 0.76 1.24 ± 0.28
25 0.31 ± 0.49 0.90 ± 0.72 1.16 ± 0.13
50 0.94 ± 0.66 0.95 ± 0.53 1.40 ± 0.12
100 1.37 ± 0.10 1.38 ± 0.25 1.61 ± 0.27 **
Data are presented as means ± SD.
A p value < 0.001 is noted as ***. A 0.001<p<0.05 is noted as ** and a 0.05<p< 0.1 is noted as *.
No significant statistical differences were noted for the BV/TV and mdV/TV, but there were significant differences in osteoid formation in the three
strains.
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TABLE 3
BSE analysis of distal femur cortical bone and thoracic vertebral body trabecular bone.
BSE analysis of distal femur cortical bone
Fluoride Treatment (ppm) A/J SWR/J 129P3/J
Peak grey level
0 212 ± 13 194 ± 14 190 ± 15
25 200 ± 22 191 ± 12 215 ± 13
50 201 ± 15 179 ± 19 210 ± 19
100 216 ± 2 210 ± 12 212 ± 13
FWHM
0 44 ± 10 39 ± 9 44 ± 8
25 36 ± 5 42 ± 7 39 ± 3
50 38 ± 4 43 ± 10 43 ± 4
100 46 ± 3 46 ± 4 45 ± 1
BSE analysis of vertebral body trabecular bone
Peak grey level
0 181 ± 15 171 ± 23 165 ± 11
25 170 ± 20 179 ± 24 171 ± 33
50 176 ± 20 180 ± 24 178 ± 8
100 193 ± 14 206 ± 18 185 ± 16
FWHM
0 55 ± 8 65 ± 6 62 ± 11
25 57 ± 9 61 ± 6 62 ± 11
50 49 ± 7 51 ± 7 *** 53 ± 8
100 53 ± 7 51 ± 6 *** 48 ± 1 *
Data are presented as means ± SD.
A p value < 0.001 is noted as***. A 0.001<p<0.05 is noted as ** and a 0.05<p< 0.1 is noted as *.
For vertebral body trabecular bone, the fluoride dose significantly affected the full width of the half maximum value (FWHM) in the SWR/J strain.
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TABLE 4
Bone mineral crystal length (002) and bone mineral crystal width (310), estimated by x-ray diffraction.
Fluoride Treatment (ppm) A/J SWR/J 129P3/J
Bone mineral crystal
length (Å)
0 147.2 ± 12.1 148.5 ± 5.9 130.4 ± 2.6
25 140.3 ± 4.4 143.6 ± 9.4 135 ± 6.8
50 146.7 ± 8.7 144.4 ± 10.6 133.5 ± 6.3
100 141 ± 3.5 148.4 ± 10.5 133.9 ± 7.0
Bone mineral crystal
width (Å)
0 56.2 ± 1.1 55.3 ± 1.4 52.2 ± 1.3
25 56.2 ± 1.0 56.4 ± 1.1 53.5 ± 1.5
50 58.5 ± 1.8 ** 58.4 ± 2.1 54.5 ± 1.0 ***
100 59.4 ± 1.1 *** 61.2 ± 2.2 *** 56.4 ± 1.0 ***
Data are presented as means ± SD.
A p value < 0.001 is noted as ***. A 0.001<p<0.05 is noted as ** and a 0.05<p< 0.1 is noted as *.
The fluoride treatment did not significantly affect the crystal length, but it induced a significant increase of the crystal width in all three strains. The crystal
length and width were significantly smaller in the strain 129P3/J (p<0.05), compared to the other two strains.
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TABLE 6
Microhardness of trabecular and cortical bone in vertebral bodies (VB), and of cortical bone in distal femurs in each
treatment group.
Fluoride Treatment (ppm) Strain A/J Strain SWR/J Strain 129P3/J
VB microhardness for
trabecular bone
0 27.6 ± 2.1 25.1 ± 2.5 25.9 ± 1.7
100 24.5 ± 2.4 24.8 ± 3.2 25.6 ± 1.7
VB microhardness for
cortical bone
0 31.1 ± 2.0 30.3 ± 0.9 31.7 ±1.7
100 31.4 ± 3.1 30.6 ± 1.6 31.4 ± 1.3
Distal femur cortex
microhardness
0 39.4 ± 1.5 36.8 ± 2.3 37.9 ± 2.6
100 38.0 ± 2.5 35.3 ± 1.0 37.5 ± 1.7
Data are presented as means ± SD. No statistical difference was noted for the microhardness of cortical and trabecular bone in the three strains.
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